null Connected Health in Treatment
Manager Insights

Connected Health in Treatment

Manager Insights Article Thematic Equity
April 2020
Connected Health in Treatment

Authors & Contributors

Matthew Jenkin

Matthew Jenkin

Rick Rosania, CFA

Rick Rosania, CFA

Kyle McDonough, CFA

Kyle McDonough, CFA

The advent of COVID-19 has brought with it many changes. Specifically, trends in connected health are rapidly emerging as the pandemic disrupts global markets, supply chains and consumer confidence. In our first article, we examine the impact of COVID-19 on telemedicine and why we expect this trend to persist. Our latest article discusses how existing treatment options can help to both treat patients and report critical data in real time.

Therapeutics with Telemedicine

Life will be different once the current COVID-19 pandemic comes to an end, and we believe many connected health companies will emerge stronger from the resulting permanent changes in our everyday lives. One consistent theme that we find throughout our universe is increased offerings of at-home care products combined with a remote monitoring function for clinicians. Given the current impact of COVID-19, respiratory ailments and shrinking hospital capacity issues are top-of-mind. We believe a simpler and timelier treatment would be to take advantage of wearable monitoring and treatment technology (wearables) that patients may already feel comfortable using in their everyday lives. Through our Connected Health thematic research we unearthed an innovative solution: wearable vests that act as airway clearance systems and remotely monitor vital signs.

The wearable is a Bluetooth-enabled vest currently worn by patients with chronic lung disease. The device manages this illness by maintaining lung function and virtually connecting the patient and their data with doctors. Worn at home, the vest applies gentle pressure to the chest wall, treating all lobes of the lung. It effectively removes accumulated secretions, reduces exacerbations, and allows for easier breathing. In a study by the Department of Pediatrics, University of Minnesota, a vest was found to improve pulmonary function for 94% of Cystic Fibrosis patients that used the vest for 22 months versus traditional methods.1 The vest is not intended to treat any specific underlying disease, but rather to provide airway clearance therapy. We potentially see this as an option for COVID-19 patients struggling to breathe, providing dual benefits: vests could help with breathing and removing lung secretions while also sending data to doctors who help monitor the severity of the illness as it progresses or heals.

As discussed in our first installment of our Connected Health series on Telemedicine, we believe the outbreak of COVID-19 has forced clinicians to innovate. Once the pandemic has waned, we think prescribed use of this respiratory innovation will continue to proliferate as the virus establishes familiarity. While there will be many unique and potentially revolutionary solutions for how we navigate COVID-19 over time, our research invariably returns to a key principle: the simplest solution is almost always the best one. We believe examples like wearable vests are simple, economical, and ready-to-use solutions that can help manage COVID-19.

Telemedicine image

 

Discover the building blocks to own the future >>

 

https://www.ncbi.nlm.nih.gov/pubmed/1758749

PAST PERFORMANCE IS NOT NECESSARILY INDICATIVE OF FUTURE RESULTS. Mellon Investments Corporation (“Mellon”) is a registered investment advisor and subsidiary of The Bank of New York Mellon Corporation (“BNY Mellon”). Any statements of opinion constitute only current opinions of Mellon, which are subject to change and which Mellon does not undertake to update. This publication or any portion thereof may not be copied or distributed without prior written approval from the firm. Statements are correct as of the date of the material only. This document may not be used for the purpose of an offer or solicitation in any jurisdiction or in any circumstances in which such offer or solicitation is unlawful or not authorized. The information in this publication is for general information only and is not intended to provide specific investment advice or recommendations for any purchase or sale of any specific security. Some information contained herein has been obtained from third party sources that are believed to be reliable, but the information has not been independently verified by Mellon. Mellon makes no representations as to the accuracy or the completeness of such information. No investment strategy or risk management technique can guarantee returns or eliminate risk in any market environment and past performance is no indication of future performance. The indices referred to herein are used for comparative and informational purposes only and have been selected because they are generally considered to be representative of certain markets. Comparisons to indices as benchmarks have limitations because indices have volatility and other material characteristics that may differ from the portfolio, investment or hedge to which they are compared. The providers of the indices referred to herein are not affiliated with Mellon, do not endorse, sponsor, sell or promote the investment strategies or products mentioned herein and they make no representation regarding the advisability of investing in the products and strategies described herein. Please see mellon.com for important index licensing information. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.